Stayble Therapeutics AB publishes prospectus relating to the issuance of units in connection with the intended listing on Nasdaq First North Growth Market
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
Stayble Therapeutics AB (“Stayble” or the “Company”) has composed a prospectus for the issuance of units to institutional investors and the public in Sweden in connection with the intended listing of the Company’s share on Nasdaq First North Growth Market (“Nasdaq First North”). The prospectus, approved and registered with the Swedish Financial Supervisory Authority today January 31, 2020, is available on the Company’s webpage (www.staybletherapeutics.com) and on Mangold Fondkommission’s webpage (www.mangold.se). The prospectus will also be made available on the Swedish Financial Supervisory Authority´s webpage (www.fi.se).
Subscription forms, teaser and other information regarding the issuance of units and the listing of the Company’s share on Nasdaq First North will be made available on the Company’s and Mangold’s webpages on February 4 when the subscription period commence.
Mangold Fondkommission AB are financial advisors and Advokatfirman Schjødt are legal advisors in connection with the Offering.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
+46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and requires minimal rehabilitation. The Company’s focus is set upon the continued clinical development of the upcoming phase 2b study. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.
Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions by law and recipients of this press release in jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Stayble in any jurisdiction, neither from Stayble nor from someone else.
Any investment decision by reason of the Offering must be made on the basis of all publicly available information relating to the Company. Such information has not been independently verified by the Company's financial advisor. The information contained in this announcement is for background purposes only and does not purport to be complete. Thus, an investor should not solely rely on the information contained in this announcement or its accuracy or completeness.
This press release does not constitute or form part of an offer or solicitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.
The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, New Zealand, Hong Kong, Japan, Canada, New Zealand or South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
This press release is not a prospectus or EU Growth prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.